基本情報
研究キーワード
4経歴
1-
2009年 - 現在
学歴
2-
- 1987年
-
- 1987年
委員歴
11受賞
12論文
293-
European heart journal. Cardiovascular Imaging 2025年1月2日
-
Hypertension research : official journal of the Japanese Society of Hypertension 47(12) 3345-3355 2024年12月Previous studies have reported that blood pressure variability (BPV) is associated with the risk of cardiovascular events independent of blood pressure (BP) levels. While there is little evidence from intervention trials examining whether suppressing BPV is useful in preventing cardiovascular disease, it is suggested that detection of abnormally elevated BPV may be useful in reducing cardiovascular events adding by complementing management of appropriate BP levels. Cuffless BP devices can assess beat-to-beat BPV. Although cuffless BP monitoring devices have measurement accuracy issues that need to be resolved, this is an area of research where the evidence is accumulating rapidly, with many publications on beat-to-beat BPV over several decades. Ambulatory BP monitoring (ABPM) can assess 24-hour BPV and nocturnal dipping patterns. Day-to-day BPV and visit-to-visit BPV are assessed by self-measured BP monitoring at home and office BP measurement, respectively. 24 h, day-to-day, and visit-to-visit BPV have been reported to be associated with cardiovascular prognosis. Although there have been several studies comparing whether ABPM and self-measured BP monitoring at home is the superior measurement method of BPV, no strong evidence has been accumulated that indicates whether ABPM or self-measured home BP is superior. ABPM and self-measured BP monitoring have their own advantages and complement each other in the assessment of BPV.
-
Hypertension research : official journal of the Japanese Society of Hypertension 47(10) 2800-2810 2024年10月Hypertension (HTN) is one of the major risk factors for developing atrial fibrillation (AF), and it has been estimated that approximately 70% of hypertensive patients are at risk of developing AF. On the other hand, 60-80% of AF patients have HTN. These two diseases share many risk factors such as diabetes mellitus, obesity, alcohol consumption, and sleep apnea syndrome during their onset and disease progression. The mutual presence of these diseases has the potential to create a negative spiral, exacerbating each other's impact and ultimately leading to cardiovascular events such as heart failure and cerebrovascular disorders, thereby increasing mortality rates. With regard to the treatment of HTN, the variety of antihypertensive drugs and treatment options have significantly increased. Alongside the widespread adoption of antihypertensive therapy, a certain level of efficacy has been recognized in suppressing the incidence of new-onset AF. Catheter ablation is an established and effective treatment for AF. However, a notable recurrence rate persists. In recent years, management of these multiple risk factors has been recognized to be essential for suppressing AF recurrence, and recent guidelines for AF underscore the significance of proactively managing these risks before treatment. Notably, effective HTN management assumes paramount importance given its impact on the morbidity of AF patients. This review summarizes the correlation between HTN control before and after ablation and the risk of AF recurrence. The focus is on elucidating the pathophysiological background and its impact on clinical outcomes.
-
International journal of cardiology. Heart & vasculature 54 101507-101507 2024年10月BACKGROUND: Polypharmacy is associated with an increased risk of adverse events due to the higher number of drugs used. This is particularly notable in patients with chronic coronary syndrome (CCS), who are known to use a large number of drugs. Therefore, we investigated polypharmacy in patients with CCS, using CLIDAS, a multicenter database of patients who underwent percutaneous coronary intervention. METHOD AND RESULTS: Between 2017 and 2020, 1411 CCS patients (71.5 ± 10.5 years old; 77.3 % male) were enrolled. The relationship between cardiovascular events occurring during the median follow-up of 514 days and the number of drugs at the time of PCI was investigated. The median number of drugs prescribed was nine. Major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, stroke, heart failure, transient ischemic attack, or unstable angina, occurred in 123 patients, and all-cause mortality occurred in 68 patients. For each additional drug, the adjusted hazard ratios for MACE and all-cause mortality increased by 2.069 (p = 0.003) and 1.102 (p = 0.010). The adjusted hazard ratios for MACE and all-cause mortality were significantly higher in the group using nine or more drugs compared to the group using eight or fewer drugs (1.646 and 2.253, both p < 0.001). CONCLUSION: This study showed that an increase in the number of drugs used for CCS may be associated with MACE and all-cause mortality. In patients with CCS, it might be beneficial to minimize the number of medications as much as possible, while managing comorbidities and using guideline-recommended drugs.
MISC
224-
HYPERTENSION 56(5) 765-773 2010年11月 査読有り
-
JOURNAL OF HYPERTENSION 28(8) 1752-1760 2010年8月 査読有りObjectives There has been no report investigating the impact of the arterial stiffness reduction induced by antihypertensive medications on the improvement of target organ damage in hypertension. The aim of this study was to assess the association of the change in pulse wave velocity (PWV) with that in urinary albumin excretion as a measure of renal damage. Methods We studied 404 treated hypertensive patients (mean age, 70.5 +/- 9.5 years), who were allocated to either an active treatment group (doxazosin and atenolol when needed) or a control group. Blood pressure, urinary albumin-to-creatinine ratio (UACR), and brachial-ankle PWV (baPWV) were measured at baseline and after 6 months of treatment. Results In the total population, home/office SBP, UACR, and baPWV decreased significantly from the baseline. In multivariate regression analyses, Delta baPWV was significantly associated with Delta UACR, independent of Delta home SBP (beta=0.21, P<0.001). When the patients were divided into a group with Delta baPWV of at least 0 cm/s (positive Delta PWV) and a group with Delta baPWV of less than 0 cm/s (negative Delta PWV), the reduction of UACR was greater in the latter group, even after adjustment for the covariates including the change in home SBP. These results were essentially the same when office SBP was entered in place of home SBP, and similar both in the active treatment group and the control group. Conclusion These findings suggest that the arterial stiffness reduction induced by antihypertensive medications is associated with the improvement of renal damage, independent of home/office SBP reduction. J Hypertens 28: 1752-1760 (c) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
-
JOURNAL OF HYPERTENSION 28(7) 1574-1583 2010年7月 査読有りObjectives To study the impact of the dosing time of an angiotensin II receptor blocker (ARB) titrated by self-measured home blood pressure (HBP) on cardiorenal damage in hypertensives. Methods We conducted an open-label multicenter trial, the J-TOP study, that enrolled 450 hypertensives with self-measured systolic HBP more than 135 mm Hg. The study patients were stratified into three groups according to the difference between their morning and evening SBPs difference: a morning hypertension group (morning and evening difference at least 15 mm Hg; n=170), a morning and evening hypertension group (0 mm Hg <= morning and evening difference <15 mm Hg; n=198), and an evening hypertension group (morning and evening difference <0 mm Hg; n=82). Individuals were then randomly allocated to receive bedtime dosing or awakening dosing of candesartan (+/-diuretic as needed) titrated to achieve a target systolic HBP less than 135 mm Hg. The 6-month change in the urinary albumin/creatinine ratio (UACR) was assessed. Results In total patients, the UACR was more markedly reduced in the bedtime-dosing group than in the awakening-dosing group (-45.7 vs. -34.5%, P=0.02), whereas there were no differences in the reduction of any of the HBPs including the sleep blood pressures (BPs) between the two groups. Among the three subgroups stratified by the morning and evening difference, the difference in the UACR reduction between the bedtime-dosing and awakening-dosing groups was only significant in the morning hypertension group (-50.6 vs. -31.3%, P=0.02). Conclusion In HBP-guided antihypertensive treatment in hypertensives, bedtime dosing of an ARB may be superior to awakening dosing for reducing microalbuminuria. J Hypertens 28: 1574-1583 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
-
診断と治療 98(1) 127-134 2010年1月
-
日本臨床 67 120-126 2009年11月
-
医学のあゆみ 231(5) 465-472 2009年10月31日
-
日本血栓止血学会誌 = The Journal of Japanese Society on Thrombosis and Hemostasis 19(4) 445-446 2008年8月1日
-
医学のあゆみ 224(12) 903-909 2008年3月22日
-
Circulation journal : official journal of the Japanese Circulation Society 72 45-46 2008年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 72 25-25 2008年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 72 437-438 2008年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 72 472-472 2008年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 72 652-652 2008年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 72 215-215 2008年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 72 216-216 2008年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 72 216-216 2008年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 72 412-412 2008年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 72 322-322 2008年3月1日
-
JOURNAL OF HYPERTENSION 25(8) 1573-1575 2007年8月
-
AMERICAN JOURNAL OF HYPERTENSION 20(7) 720-727 2007年7月Background: It is reported that blood pressure (BP) variability increases with aging, and cognitive dysfunction may be related to BP variability; however, there are no data showing that exaggerated BP variability is associated with cognitive dysfunction or quality of life (QOL) in the older elderly. We investigated the relationships and the differences between ambulatory BP variability and cognitive function or QOL in younger elderly and very elderly. Methods: We recruited both 101 very elderly (aged >= 80 years) and 101 younger elderly (aged 61 to 79 years). Twenty-four-hour ambulatory blood pressure monitoring, mini-mental state examinations (MMSE), and Medical Outcome Study Short-Form 36 Items Health Survey (SF-36) were performed for all subjects. Results: The mean standard deviation (SD) of daytime systolic BP in young elderly was 17.2 +/- 4.6 mm Hg (mean SD SD of mean SD), and that in very elderly was 21.2 +/- 4.3 mm Hg. The MMSE score significantly decreased with the tertile of SD of daytime systolic BP in very elderly (P = .004) and young elderly (P = .03). In very elderly, there was no significant association between the SD of daytime systolic BP and each of eight SF-36 categories. On the other hand, in younger elderly, two of eight SF-36 categories decreased with the tertile of SID of daytime systolic BP (P = .001 for Vitality and P = .003 for Role emotion). Conclusions: Very elderly had larger BP variability than younger elderly. Exaggerated ambulatory BP variability was related to cognitive dysfunction in the elderly, especially in the very elderly, and was related to lower QOL in the younger elderly. Am J Hypertens 2007;20: 720-727 (c) 2007 American Journal of Hypertension, Ltd.
-
Circulation journal : official journal of the Japanese Circulation Society 71 871-871 2007年4月20日
-
AMERICAN JOURNAL OF HYPERTENSION 20(4) 385-391 2007年4月Background: Masked hypertension (MHT: normal office blood pressure [BP] + elevated BP out of the office) is a significant predictor of target organ damage and cardiovascular disease. The purpose of this study was to investigate the subclinical arterial damage in unmedicated subjects with MHT detected by home BP measurement. Methods: We recruited 282 subjects not taking antihypertensive medication, who had at least one of the following five cardiovascular risk factors: high BP, hyperlipidemia, diabetes mellitus, current smoking, and chronic kidney disease. Furthermore, we classified them into four groups (normotension [NT], white-coat hypertension [WCHT], MHT, and sustained hypertension [SHT]) by office BP (140/90 mm Hg) and home BP (135/85 mm Hg) measurements. Arterial damage was evaluated by measuring carotid intima-media thickness (IMT) and brachial-ankle pulse wave velocity (baPWV). Results: Subjects with MHT had a higher prevalence of habitual alcohol drinkers than the other groups, and higher pulse rates at home than those with NT and WCHT. After adjustment for covariates, carotid IMT was the highest in MHT among the four groups (mean: 1.01 v 0.83 mm for NT, 0.86 mm for WCHT, and 0.91 mm for SHT, all P<.01). The baPWV was also significantly higher in MHT than NT and WCHT (mean: 1940 v 1663 and 1733 cm/sec, all P<.01), whereas the difference between MHT and SHT (2023 cm/sec) was not significant. Conclusions: This study shows that masked hypertensives detected by home BP are at higher risk for increased arterial damage than normotensives or white-coat hypertensives, and potentially than sustained hypertensives.
-
Circulation journal : official journal of the Japanese Circulation Society 71 144-144 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 143-144 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 144-144 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 144-144 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 461-462 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 463-464 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 418-418 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 423-423 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 423-423 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 174-175 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 233-233 2007年3月1日
所属学協会
11Works(作品等)
2共同研究・競争的資金等の研究課題
28-
日本学術振興会 科学研究費助成事業 2022年4月 - 2027年3月
-
日本学術振興会 科学研究費助成事業 2020年4月 - 2025年3月
-
日本学術振興会 科学研究費助成事業 2020年7月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2019年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2018年4月 - 2023年3月